Enrollment in Merck, Endocyte vintafolide study stopped for futility
This article was originally published in Scrip
Executive Summary
Endocyte's stock sank and Merck & Co's shares stumbled on 2 May after the partners halted enrollment in a Phase III clinical trial evaluating Vynfinit (vintafolide) in the treatment of ovarian cancer, throwing into doubt early approval in Europe.